Company Analysis

Zura Bio Limited (ZURA)

Nasdaq: ZURA · Biological Products, (No Diagnostic Substances) · La Jolla, CA · filing with the SEC since 2021
Grade4.7
◀ Past 2.9● Present 3.9▶ Future 6.6
6 est.
The companyfiscal 2025, as filed
Revenuen/a
Net income-$68.7M-31.0%
Earnings per share$-1.06-76.7%
Operating cash flow-$64.8M-130.9%
Cash$109M-38.0%
Debtn/a
Shareholders’ equity$102M-30.8%
Shares, diluted94.2M+25.4%
Return on equity-67.6%
The recordfrom its filings
Filings in 202666
Newest filingNov 9 · 8-K
Annual reportMar 19, 2026
Quarterly reportOct 27, 2026
Next report due10-K by Mar 31
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents grantedn/a
Filer category<br>Emerging growth company
Trailing twelve months to Sep 2026Net income -$93.5MCash from operations -$64.8Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
22232425
As filed, in USD. Nothing here is a forecast.

News

Nov 9, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
Nov 3, 2026 · SEC EDGAR · Form EFFECT
Registration effective
Open the filing on sec.gov
Oct 27, 2026 · SEC EDGAR · Form 8-K
Results released
Open the filing on sec.gov
Oct 27, 2026 · SEC EDGAR · Form 10-Q
Quarterly report
Open the filing on sec.gov
Oct 27, 2026 · SEC EDGAR · Form S-3
Shelf registration
Open the filing on sec.gov
Aug 17, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton ZURA · research, not advice